Atlas Wealth LLC Purchases 32,801 Shares of Thermo Fisher Scientific Inc. $TMO

Atlas Wealth LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 804.1% in the first quarter, Holdings Channel.com reports. The institutional investor owned 36,880 shares of the medical research company’s stock after acquiring an additional 32,801 shares during the period. Thermo Fisher Scientific comprises approximately 2.2% of Atlas Wealth LLC’s investment portfolio, making the stock its 15th biggest holding. Atlas Wealth LLC’s holdings in Thermo Fisher Scientific were worth $18,128,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. Cornerstone Planning Group LLC increased its stake in Thermo Fisher Scientific by 22.6% in the first quarter. Cornerstone Planning Group LLC now owns 239 shares of the medical research company’s stock worth $111,000 after purchasing an additional 44 shares during the period. Gryphon Financial Partners LLC boosted its position in Thermo Fisher Scientific by 11.0% in the 1st quarter. Gryphon Financial Partners LLC now owns 2,637 shares of the medical research company’s stock valued at $1,296,000 after buying an additional 261 shares during the period. Assetmark Inc. increased its position in shares of Thermo Fisher Scientific by 56.0% during the first quarter. Assetmark Inc. now owns 58,741 shares of the medical research company’s stock worth $28,873,000 after acquiring an additional 21,087 shares during the period. PeakShares LLC boosted its holdings in shares of Thermo Fisher Scientific by 22.1% in the first quarter. PeakShares LLC now owns 2,241 shares of the medical research company’s stock valued at $1,102,000 after purchasing an additional 405 shares during the period. Finally, Main Street Group LTD purchased a new position in Thermo Fisher Scientific during the 1st quarter worth $32,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Down 2.0%

Shares of NYSE:TMO opened at $532.17 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $197.77 billion, a PE ratio of 29.26, a PEG ratio of 2.41 and a beta of 0.87. The business has a 50 day moving average of $484.57 and a two-hundred day moving average of $514.88. Thermo Fisher Scientific Inc. has a 12-month low of $403.36 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on TMO shares. Barclays reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research report on Thursday, June 11th. They set a “neutral” rating and a $510.00 target price for the company. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday. DZ Bank started coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They set a “buy” rating and a $610.00 price objective on the stock. Finally, Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $602.14.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.